Small-molecule inhibitors that block the interaction between CD40 and TRAF6 (TRAF-STOPs) overcome the current limitations of long-term CD40 inhibition in atherosclerosis, which has the potential to become a future therapeutic for atherosclerosis [20]. The gene discussed is TRAF6; the disease is atherosclerosis.